Uncommon Adverse Effect of Statin
(Necrotizing Autoimmune Myositis)

Dr. Gaber Ahmad Ekhtiar
Family Medicine. PHCC Qatar
jikhtiar@yahoo.com

Dr. Ismail Nasir Alsmadi
Family Medicine. PHCC Qatar
ismadi65@hotmail.com

Abstract

Statin-associated necrotizing autoimmune myositis (NAM) is an autoimmune condition characterized by severe acute-onset proximal muscle weakness, a very high creatinine kinase (CK) level, and prominent myofiber necrosis and minimal lymphocytic infiltration on muscle biopsy. Unlike self-limited statin myopathy, this condition usually requires aggressive immunomodulation therapy to assist recovery and prevent future disability.

Keywords: necrotizing autoimmune myositis (NAM), prominent myofiber necrosis, lymphocytic infiltration, Statins, solumedrol.

الملخص:
التهاب عضلات المناعة الذاتية الناخر المرتبط بالستاتين (NAM) هو حالة من أمراض المناعة الذاتية تتميز بضعف حاد شديد في العضلات القريبة ، ومستوى عالٍ جدًا من الكرياتينين كيناز (CK) ، ونخر ليفي عضلي بارز ، وتسلل ليمفاوي ضئيل في خزعة العضلات. على عكس اعتلال عضلي الستاتين المحدود ذاتيًا ، تتطلب هذه الحالة عادةً علاجًا قويًا لتعديل المناعة للمساعدة في التعافي والوقاية من الإعاقة في المستقبل.

الكلمات المفتاحية: التهاب عضلات المناعة الذاتية الناخر (NAM) ، نخر ليفي عضلي بارز ، تسلل ليمفاوي ، الستاتينات، سولوميدرولي.
1. Introduction

Statin-associated myopathy has historically been thought of as a self-limited entity associated with statin use. However, over the past decade, an autoimmune variety of statin-associated myopathy has been recognized, with different characteristics from the self-limited disease; this immune-mediated entity was initially called statin-induced immune-mediated necrotizing myopathy (IMNM) and now commonly referred to as statin-associated necrotizing autoimmune myositis (NAM) [Senecal J.L., Raynauld J.P., and Troyanov Y. 2017]. This type of myopathy usually requires aggressive immunosuppression or immunomodulation therapy with corticosteroids and/or intravenous immunoglobulin (IVIG) therapy [McGrath E. R., Doughty C. T., and Amato A. A. 2018, Mammen A. and Tiniakou E. 2015]. Although IVIG is generally well tolerated and has been shown to contribute to high recovery rates [Kassardjian C. D., Lennon V. A., Alfugham N. B., Mahler M., and Milone M. 2015], it is not without risks [Bichuetti-Silva D. C., Furlan F. P., Nobre F. A. et al. 2014]. In this case report, we present a patient who developed posterior reversible encephalopathy syndrome (PRES), thought to be a possible delayed adverse reaction to receiving IVIG for treatment of statin-associated NAM.

2. Case Presentation

A 42 year-old woman with past medical history of type 2 diabetes mellitus, hyperlipidemia, presented to the emergency department with progressive bilateral weakness over 6 months. She reported weakness that began in her lower extremities and then progressed to her upper extremities, affecting primarily her proximal muscle strength. She had no associated numbness or tingling, fevers, chills, headache, rashes or skin changes, joint pain, or recent injury. Her medications included metformin, gliclazide, aspirin.
She was also on a high-intensity statin for the past year without any recent dosage changes.

Physical examination was significant for reduced muscle strength involving the neck, bilateral deltoids, and quadriceps. She appeared unsteady on her feet with a slightly widened gait. Deep tendon reflexes, sensation, and coordination were intact throughout all extremities. Initial labs were significant for a leukocytosis of 10,500K/cumm, aspartate aminotransferase (AST) of 800U/L, alanine transferase (ALT) of 750U/L, erythrocyte sedimentation rate (ESR) of 35mm/hr, and markedly elevated creatinine kinase (CK) of 20,000 U/L. ANA was 1: 80 and the anti-dsDNA antibody was negative. Magnetic resonance imaging (MRI) of the patient's pelvis revealed extensive edema throughout the proximal pelvic musculature with a symmetric distribution consistent with myositis. Furthermore, an electromyogram and nerve conduction study demonstrated diffuse and active irritable myopathy, and a muscle biopsy of the vastus lateralis revealed necrotizing myopathy with minimal inflammatory infiltrate and MHCL immunostaining consistent with NAM.

Given the aforementioned findings, the patient was started on high-dose intravenous solumedrol, mycophenolate mofetil, and four consecutive days of IVIG for treatment of a necrotizing myositis (NM), which resulted in improvement in the creatinine kinase down to 8,000 after a week into therapy.

About one week into the patient's treatment course, the patient developed acute bilateral vision loss and right side hemineglect. A magnetic resonance angiogram (MRA) of the head revealed development of diffuse arterial narrowing and irregularity consistent with cerebral vasospasm. Furthermore, she had areas of signal abnormality in the bilateral frontal, parietal, and occipital lobes with diffusion restriction. Consultation with neuroradiology suggested that the patient's neurological findings were consistent with PRES, suspected to
be related to a delayed reaction to IVIG therapy. The patient was subsequently started on nimodipine and magnesium. Subsequent serial MRAs and neurological exams revealed radiographic and clinical improvement, respectively. However, her vision only improved minimally at that time. She was discharged with daily mycophenolate and sent to a rehabilitation facility to continue muscle strengthening and ambulation gait training. At 6-month follow-up, she reported marked improvement in physical strength and her vision was significantly improved; her CK returned to normal levels.

3. Discussion

Based on the patient's serological, histological, and clinical findings. A diagnosis of statin-associated NAM was made (anti-HMGCR-positive subset). Although the patient had a positive PM/Sci-100 antibody and an ANA with nucleolar pattern, she did not have any extra-muscular involvement such as interstitial lung disease, inflammatory joint disease, mechanic's hands, sclerodactyly, or Raynaud's phenomenon which would typically be seen in an overlap myositis (OM), such as on OM with scleroderma. However, it remains unknown whether she will develop additional symptoms over time. Patients with an idiopathic inflammatory myopathy (IIM) or autommune inflammatory myosis (AIM) can now more routinely be classified by their autoantibody pattern associated with different disease characteristics and treatment responses [Senecal J.L., Raynaul J.P., and Troyanov Y. 2017, kassardjian C. D., lennon V. A., Alfugham N. B., Mahler M., and Milone M. 2015]; however, we have not been able to find any studies of statin-associated NAM with a patient having both anti-HMGCR and anti-PM/Sci-100 antibodies simultaneously at the time of this report.
Statin-associated NAM is an autoimmune muscle disease (and subtype of IIM) characterized by prominent myofiber necrosis and minimal lymphocytic infiltration [Christopher-Stine L. and Basharat P. 2017]. It is strongly associated with statin exposure and the development of HMG-CoA reductase antibody, although it can also occur in patients who have never taken a statin [Christopher-Stine L. and Basharat P. 2017]. Compared to a self-limited statin myopathy, statin-associated NAM is more commonly associated with clinical proximal muscle weakness, higher creatinine kinase values, HLA-DRB1*11:01 positivity, an irritable myopathy on EMG, diffuse muscle edema seen on MRI, and muscle necrosis with minimal inflammation on muscle biopsy [Christopher-Stine L. and Basharat P. 2017-Mohassel P. and Mammen A. L. 2018]. It is important to note that time of onset is variable and may occur even years after statin exposure [Christopher-Stine L. and Basharat P. 2017]. Simply discontinuing statin treatment in NAM is often inadequate as muscle damage and necrosis often continues even after cessation of the statin [Christopher-Stine L. and Basharat P. 2017,Musset L., Allenbach Y., Benveniste O. et al. Oct. 2016]. Thus, most patients require aggressive immunosuppression or immunomodulation therapy, with first-line therapy including the use of high-dose corticosteroids and/or IVIG, as well as other immunotherapies such as methotrexate, azathioprine, mycophenolate, and/or rituximab, depending on the individual patient [McGrath E. R., Doughty C. T., and Amato A. A. 2018, Mammen A. and Tiniakou E. 2015, Christopher-Stine L. and Basharat P. 2017]. Interestingly, age appears to play a role in response to therapy, with a recent cohort study finding younger patients to have more severe disease and a worse prognosis compared to older patients [Tihniakou E., Pinal-Fernandez I., Lloyd T. E. et al. 2017]. Furthermore, it appears that earlier and more intense treatment is associated with improved outcomes [kassardjian C. D., lennon V. A., Alfugham N. B., Mahler M., and Milone M. 2015,Pinal-Fernandez I., Casal-
In this case, the patient was treated with a combination of corticosteroids, IVIG, and mycophenolate given her younger age and severe disease presentation. A recent study has found that human anti-HMGCR antibodies can induce muscle weakness in mice and appear to be directly pathogenic towards muscle through a complement-mediated mechanism; thus, in the future, plasma exchanges and complement-targeting therapies may also play a role in the treatment of NAM [Bergua C., Chiavelli H., Allenbach Y. et al. 2019].

Although no randomized clinical trials have been performed to guide therapy of statin-associated NAM, IVIG has been shown to be a relatively safe and effective therapy for this autoimmune condition [kassardjian C. D., lennon V. A., Alfugham N. B., Mahler M., and Milone M. 2015, Tiniakou E. and Christopher-Stine L. 2017]. Common adverse reactions include malaise, headache, and abdominal pain, although these reactions are generally mild [Bichuetti-Silva D. C., Furlan F. P., Nobre F. A. et al. 2014]. However, IVIG has also been shown to be associated with several more serious adverse effects, including anaphylaxis, transfusion-associated lung injury, and thromboembolic events [Orange J. S., Hossny E. M., Weiler C. R. et al. 2006]; there are also a few case reports of PRES in patients receiving IVIG for neurological diseases such as Guillain-Barre and Miller-Fisher syndrome [Belmouaz S., Desport E., Leroy F. et al. 2008- Voltz R., Rosen F. V., Yousry T., Beck J., and Hohlfeld R. 1996], including a case involving amelioration of PRES after IVIG treated early on with plasma exchange/ immunoadsorption therapy [Stetefeld H. R., Lehmann H. C., Fink G. R., and Burghaus L. 2014].

In this case, the patient's initial symptom of PRES was bilateral vision loss. Intraocular pressures were within normal ranges, and bilateral corneas and lens appeared normal. A systemic vasculitis related to the patient's newly diagnosed inflammatory myositis was also considered in the differential of the patient's
neuroradiographic findings; however, the patient had interval progression of hyperintense lesions prior to improving. Thus, given the normal orbital and ocular structures, as well as the abnormal intracranial imaging findings, a diagnosis of PRES was made. In addition, the patient's clinical course suggests that IVIG may have been associated with the patient's development of PRES. The patient developed hyperintense lesions of her bilateral occipital regions and irregularities of the vertebral vessels after receiving IVIG treatment, similar to previously reported cases of PRES after administration of IVIG (although the reported timing of symptom onset in the literature is typically sooner, ranging between 24 hours after initiation of IVIG and 4-7 days after completion of IVIG therapy) [Nakajima M. 2005-Stetefeld H. R., Lehmann H. C., Fink G. R., and Burghaus L. 2014]. Furthermore, she did not have any hypertensive episodes kidney disease, signs or symptoms of infection, or electrolyte abnormalities that could otherwise explain the development of PRES [Hobson E. V., Craven I., and Blank S. C. 2012- Camara-Lemarroy C.R., Gonzalez-Moreno E.I., Ortiz-Corona J. D. J. et al. 2014].

PRES is a syndrome defined by neurological signs (most commonly headache, vomiting, and visual disturbances) and radiographic abnormalities (typically hyperintense signals on T2-weighted MR imaging especially in bilateral occipital regions, responsible for vision loss) [Belmouaz S., Desport E., Leroy F. et al. 2008]. Although little is known about the pathophysiology behind this disease process, it has been postulated that sudden changes in plasma viscosity induced by IVIG infusion, vasogenic edema, and cerebral vasospasm may lead to the development of PRES [Belmouaz S., Desport E., Leroy F. et al. 2008, Incecik F., Herguner M. O., Altunbasak S., and Yildizdas D. 2011]. Treatment of PRES involves cessation of the offending agent (in this case, the course of IVIG was already completed over one week before onset of symptoms) and strict blood pressure control when elevated [Fischer M. and Schmutzhard E. 2017]. Magnesium (often
low in patients with PRES) should be repleted given its (prophylactic) anticonvulsive and vasodilating effects [Chardain A., Mesnage V., Alamowitch S. et al. Jun 2016]. Furthermore, calcium antagonists are sometimes needed in the setting of cerebral vasospasm, as was the case in our patient [Fischer M. and Schmutzhard E. 2017, Lamy C., Oppenheim C., and Mas J. L. 2014]. Improvement in neurological signs and symptoms of variable, depending on the initial severity of imaging and types of complications (e.g., progression of vasogenic edema to cytotoxic edema and ischemia) [Gao B., Lyu C., Lerner A., and McKinney A. M. 2018].

4. Conclusion

This clinical case report describes two suspected medication-induced adverse effects (statin-associated NAM and IVIG-induced PRES) in a single patient. We hope this report will serve as an important reminder that every medication can potentially have adverse effects (common, uncommon, and atypical), that the risks and benefits of each medication treatment must be considered, and that unusual/ atypical adverse effects of even critical therapeutic medication treatment need to be recognized early, in order to optimize patient care outcomes.
References


11. Incecik F., Herguner M. O., Altunbasak S., and Yildizdas D. 2011. "Reversible posterior encephalopathy syndrome due to intravenous immunoglobulin in a child with


